Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
REGULATORY
MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
The Ministry of Health, Labor and Welfare (MHLW) plans to drive the development of so-called “drug loss” products in Japan by helping domestic pharma companies come in contact with the overseas originators of such medicines. The MHLW intends to collaborate…
To read the full story
Related Article
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- Industry Calls for More Tailored Govt Support on Drug Loss Product Development
July 16, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
May 21, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
REGULATORY
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
- Ishin Urges Takaichi to Revisit OTC-Like Drug Coverage, Softens Savings Target
December 5, 2025
- JPMA Chief Presses LDP Study Group to Lock In On-Patent Prices, Scrap “Spillover” Rule
December 5, 2025
- LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
- Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…